Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Considerations in Demonstrating Interchangeability With a Reference Product: Guidance for Industry [Docket No. FDA-2017-D-0154]” as published in the Federal Register on January 18, 2017.
All of the undersigned groups share the FDA's deep commitment to the development of a robust biosimilars market for patients, and greatly appreciate all the work the agency has done in creating certainty around the approval pathway created by the Biologics Price Competition and Innovation Act (BPCIA), including the long anticipated proposed guidance detailing the requirements of obtaining an interchangeability designation for a biosimilar.
The Academy of Managed Care Pharmacy (AMCP) thanks the Washington Department of Labor & Industries for the opportunity to provide comments in response to CR-102 Proposed Language on Interchangeable Biologics, the Prescription Drug Program and Therapeutic Interchange.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Substitute Bill No.7118 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
In support of House Bill No. 628, AMCP believes that a pilot medication therapy management (MTM) program for patients in the TennCare program will lead to higher quality care for those patients.
The Academy of Managed Care Pharmacy (AMCP) urges you to support House Bill No. 628, which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program. MTM services have demonstrated success for Medicare Part D beneficiaries by improving patient outcomes while decreasing overall health care costs, and AMCP strongly supports the expansion of MTM services for other patient groups including Medicaid beneficiaries.
The Academy of Managed Care Pharmacy (AMCP) urges you to support Senate Bill No. 398, which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program.
The Academy of Managed Care Pharmacy (AMCP) thanks the Pharmacy Quality Alliance (PQA) for the opportunity to provide comments in response to the memo titled Endorsement Consideration by PQA Members of Three New Performance Measures.
As stakeholders firmly committed to fostering patient access to affordable medicines and pharmaceutical competition, we would like to thank you for introducing the bicameral and bipartisan Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the request for information (RFI) for Medicare Advantage (MA) and Medicare Part D programs included in the “Announcement of Calendar Year (CY) 2018 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter and Request for Information” released on April 3, 2017.
The undersigned organizations thank the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities—Questions and Answers [FDA-2016-D-1307]” as published in the Federal Register on January 19, 2017.
The Fair Access for Safe and Timely (“FAST”) Generics Act would provide a clear solution to abusive, anticompetitive business practices that increase costs to the American health care system by impeding patient access to generic and biosimilar medicines.
